Skip to main content
Equibles
CRMD logo

CRMD · CorMedix Inc. · Webcasts, Transcripts & Audio

Track CRMD — free

Use CRMD with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CRMD.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$7.19 -0.23 (-3.10%) At close · Oct 2
Russell 2000 member Rebalance outlook locked
Market Cap
$611.47M
Shares
77.94M
Volume · Oct 2 1.13M Avg daily vol (3M) 1.06M

CorMedix Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for CorMedix Inc. (CRMD), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▼82.1% $6,817 −$6.85M '22 Q3 22-11-10 ▼47.3% $29,702 −$8.21M '22 Q4 23-03-30 · $806,119 −$14.15M '24 Q2 24-08-14 · $11.46M −$2.78M '24 Q3 24-10-30 · $39.08M $20.64M '25 Q1 25-04-08 ▲4829.4% $39.74M $19.83M '25 Q2 25-08-07 ▲810.2% $104.28M $108.56M '25 Q3 25-11-12 · $128.62M $14.02M '25 Q4 26-03-05 ▲226.1% $127.43M $38.60M '26 Q1 26-05-14 LATEST ▲156.5% $101.93M $25.99M '26 Q2 26-08-13
Conference
Investor event
2026-09-09
CorMedix Inc. (CRMD) September 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-13
CorMedix Inc. (CRMD) Q2 2026 Earnings Call
Revenue
$101.93M
▲ 156.5% YoY
Diluted EPS
$0.29
▲ 3.6% YoY
Gross margin
75.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-14
CorMedix Inc. (CRMD) Q1 2026 Earnings Call Transcript
Confident tone DefenCath commercial performance and TDAPA transition ReZZAYO ReSPECT Phase III results and sNDA preparation NUTRI-GUARD TPN Phase III enrollment challenges
Revenue
$127.43M
▲ 226.1% YoY
Diluted EPS
$0.43
▲ 43.3% YoY
Gross margin
82.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-03-11
CorMedix Inc. (CRMD) March 2026 Conference
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-03-10
CorMedix Inc. (CRMD) March 2026 Conference
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY25 · Q4
2026-03-05
CorMedix Inc. (CRMD) Q4 2025 Earnings Call Transcript
Positive tone DEFENCATH TDAPA transition 2026/2027 financial guidance and adjusted EBITDA RIZEAO Phase III RESPECT trial
Revenue
$128.62M*
Gross margin
83.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Capital Markets Day
Investor event
2026-02-10
CorMedix Inc. (CRMD) February 2026 Capital Markets Day
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-01-12
CorMedix Inc. (CRMD) January 2026 Conference
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY25 · Q3
2025-11-12
CorMedix Inc. (CRMD) Q3 2025 Earnings Call Transcript
Confident tone DefenCath commercial performance and TDAPA Melinta acquisition and integration Pricing and ESRD rule/legislation
Revenue
$104.28M
▲ 810.2% YoY
Diluted EPS
$1.26
Gross margin
89.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
CorMedix Inc. (CRMD) Q2 2025 Earnings Call Transcript
Confident tone DefenCath Commercial Launch / LDO Rollout Melinta Therapeutics Acquisition Capital Structure and Financing
Revenue
$39.74M
▲ 4829.4% YoY
Diluted EPS
$0.28
Gross margin
95.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-04-08
CorMedix Inc. (CRMD) Q1 2025 Earnings Call Transcript
Confident tone DefenCath commercial launch and net sales TDAPA reimbursement and Medicare Advantage Inpatient hospital growth
Revenue
$39.08M
Diluted EPS
$0.30
Gross margin
95.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-25
CorMedix Inc. (CRMD) Q4 2024 Earnings Call Transcript
Confident tone Commercial launch and revenue ramp Large dialysis organization (LDO) customer Inpatient commercialization strategy
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-10-30
CorMedix Inc. (CRMD) Q3 2024 Earnings Call Transcript
Confident tone DefenCath Commercial Launch Dialysis Customer Expansion Adult TPN Clinical Program
Revenue
$11.46M
Diluted EPS
$-0.05
Gross margin
94.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-14
CorMedix Inc. (CRMD) Q2 2024 Earnings Call Transcript
Confident tone DefenCath commercial launch (inpatient and outpatient) TDAPA and Medicare Advantage reimbursement TPN label expansion opportunity
Revenue
$806,119
Diluted EPS
$-0.25
Gross margin
36.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
CorMedix Inc. (CRMD) Q1 2024 Earnings Call Transcript
Confident tone Commercial launch of DefenCath Label expansion and pediatric study Post-marketing real-world evidence studies
Diluted EPS
$-0.25
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-03-12
CorMedix Inc. (CRMD) Q4 2023 Earnings Call Transcript
Confident tone DefenCath commercial launch Reimbursement and CMS review Hospital formulary adoption process
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-14
CorMedix Inc. (CRMD) Q3 2023 Earnings Call Transcript
Diluted EPS
$-0.17
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
CorMedix Inc. (CRMD) Q2 2023 Earnings Call Transcript
Diluted EPS
$-0.25
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-15
CorMedix Inc. (CRMD) Q1 2023 Earnings Call Transcript
Diluted EPS
$-0.24
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-30
CorMedix Inc. (CRMD) Q4 2022 Earnings Call Transcript
Revenue
$29,702*
▼ 47.3% YoY
Gross margin
98.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-10
CorMedix Inc. (CRMD) Q3 2022 Earnings Call Transcript
Revenue
$6,817
▼ 82.1% YoY
Diluted EPS
$-0.17
Gross margin
78.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-11
CorMedix Inc. (CRMD) Q2 2022 Earnings Call Transcript
Revenue
$21,253
▲ 159.5% YoY
Diluted EPS
$-0.19
Gross margin
98.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-12
CorMedix Inc. (CRMD) Q1 2022 Earnings Call Transcript
Revenue
$7,636
▼ 91.3% YoY
Diluted EPS
$-0.18
Gross margin
80.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-29
CorMedix Inc. (CRMD) Q4 2021 Earnings Call Transcript
Revenue
$56,396*
▲ 1.2% YoY
Gross margin
14.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-09
CorMedix Inc. (CRMD) Q3 2021 Earnings Call Transcript
Revenue
$38,088
▼ 59.1% YoY
Diluted EPS
$-0.22
Gross margin
33.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-12
CorMedix Inc. (CRMD) Q2 2021 Earnings Call Transcript
Revenue
$8,191
▼ 50.2% YoY
Diluted EPS
$-0.12
Gross margin
-76.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-14
CorMedix Inc. (CRMD) Q1 2021 Earnings Call Transcript
Revenue
$88,261
▲ 19.2% YoY
Gross margin
30.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-03-30
CorMedix Inc. (CRMD) Q4 2020 Earnings Call Transcript
Revenue
$55,714*
▲ 124.9% YoY
Gross margin
-2.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-05
CorMedix Inc. (CRMD) Q3 2020 Earnings Call Transcript
Revenue
$93,020
▲ 56.3% YoY
Gross margin
14.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-10
CorMedix Inc. (CRMD) Q2 2020 Earnings Call Transcript
Revenue
$16,443
▼ 53.4% YoY
Gross margin
-16.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-11
CorMedix Inc. (CRMD) Q1 2020 Earnings Call Transcript
Revenue
$74,054
▼ 54.8% YoY
Gross margin
34.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-03-16
CorMedix Inc. (CRMD) Q4 2019 Earnings Call
Revenue
$24,778*
▼ 6.6% YoY
Gross margin
-86.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–32 of 32 webcasts
Key facts CIK 1410098 CUSIP 21900C308 13F (30d) 3 filings 3 filers Visit website Investor relations